Lophius Biosciences Concludes TB Detection Trials
News Nov 08, 2012
Lophius Biosciences has reported its first successfully concluded clinical Proof of Principle study with respect to detection of active tuberculosis (TB) using its novel T-Track® TB test which is based on Lophius Biosciences proprietary Reverse T Cell Technology (RT Technology).
The clinical Proof of Principle was concluded in India with a cohort of 44 patients. Results demonstrate that the T-Track® TB test was able to detect active TB in in 10 of 12 non-treated patients. Besides its high sensitivity and specificity the T-Track® TB test also demonstrated a remarkably short turnaround time of 2 days which compares favorably to currently used classical detection methods. In summary, these results imply that the T-Track® TB test could represent an innovative and fast detection approach for this area of strong medical need.
For further test development Lophius Biosciences has been awarded research funding of 140K EUR under the scope of the ZIM-solo-program from the German government. This funding should help to broaden the scope of the T-Track® TB tests with respect to detection of latent TB and potential patient-monitoring of treated TB subjects. The company will present first results at Medica mid November 2012 in Düsseldorf.
"We are very pleased to have accomplished clinical Proof of Principle for our second proprietary technology platform. Our short-term goal is geared towards test optimization and further validation in a bigger patient cohort" said Dr. Michael Lutz, CEO of Lophius Biosciences.
Genomics Researchers Showcase their Applications of Droplet Digital PCR at ASHG 2017 Annual MeetingNews
The sensitivity and reliability of Droplet Digital PCR will be showcased in over a dozen presentations at the American Society of Human Genetics (ASHG) 2017 Annual Meeting.READ MORE
Aqueous Humor Could Help Direct Retinoblastoma TreatmentNews
Study demonstrates that aqueous humor removed during chemotherapy treatment contains tumor DNA, which could be used for a surrogate 'liquid' biopsy.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018